Histologic changes in Chinese patients with chronic hepatitis B virus infection after interferon-alpha therapy
- PMID: 1415022
- DOI: 10.1093/ajcp/98.4.402
Histologic changes in Chinese patients with chronic hepatitis B virus infection after interferon-alpha therapy
Abstract
To evaluate the histologic effects of interferon-alpha (IFN alpha) therapy on chronic hepatitis B virus (HBV) infection, a semiquantitative study using a modified Knodell's numeric histologic scoring system was performed on paired pre- and post-treatment liver biopsy specimens from 127 adult Chinese patients from two trials of IFN alpha therapy (IFN alpha, n = 86; control, n = 41). The effects of IFN alpha therapy on the hepatic expression of HBV antigens were also determined using immunohistochemical analysis. Serologic response with clearance of HBV e antigen (n = 18) was associated with reduction in lobular activity, periportal piecemeal necrosis, portal inflammation, and total histologic scores. Loss of HBV e antigen also was associated with a reduction in the amount of HBV core antigen in the hepatocytes. In contrast, there was an increase in hepatic expression of HBV surface antigen after IFN alpha therapy. Patients who lost HBV e antigen with IFN alpha therapy were characterized by more severe initial periportal piecemeal necrosis before treatment. These data indicate that (1) serologic response is associated with a reduction in hepatic HBV replication and an improvement in hepatic histology, and (2) patients with severe periportal piecemeal necrosis respond more favorably to IFN alpha therapy.
Similar articles
-
Hepatic expression of viral antigens, hepatocytic proliferative activity and histologic changes in liver biopsies of children with chronic hepatitis B after interferon-alpha therapy.Liver. 1999 Oct;19(5):369-74. doi: 10.1111/j.1478-3231.1999.tb00064.x. Liver. 1999. PMID: 10533793 Clinical Trial.
-
Relationship between the serum alanine aminotransferase level at the end of interferon treatment and histologic changes in wild-type and precore mutant hepatitis B virus infections.J Viral Hepat. 1996 May;3(3):137-42. doi: 10.1111/j.1365-2893.1996.tb00004.x. J Viral Hepat. 1996. PMID: 8871872 Clinical Trial.
-
Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP).Hepatology. 1999 Jul;30(1):277-82. doi: 10.1002/hep.510300117. Hepatology. 1999. PMID: 10385667 Clinical Trial.
-
Heterogeneity of immune control in chronic hepatitis B virus infection: Clinical implications on immunity with interferon-α treatment and retreatment.World J Gastroenterol. 2022 Oct 28;28(40):5784-5800. doi: 10.3748/wjg.v28.i40.5784. World J Gastroenterol. 2022. PMID: 36353205 Free PMC article. Review.
-
The management of chronic hepatitis B.Am J Med. 1994 Jan 17;96(1A):34S-39S; discussion 39S-40S. doi: 10.1016/0002-9343(94)90188-0. Am J Med. 1994. PMID: 8109587 Review.
Cited by
-
Hepatic disorders. Features and appropriate management.Drugs. 1995 Jan;49(1):83-102. doi: 10.2165/00003495-199549010-00007. Drugs. 1995. PMID: 7705218 Review.
-
Hepatic expression of interferon-alpha in chronic hepatitis B virus infection.Dig Dis Sci. 1994 Sep;39(9):2014-21. doi: 10.1007/BF02088140. Dig Dis Sci. 1994. PMID: 8082512
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical